Anti-osteoporosis drug use: too little, too much, or just right? The HUNT study, Norway
Use of anti-osteoporotic drugs (AODs) was examined in a Norwegian population 50–85 years. Among them with Fracture Risk Assessment Tool (FRAX) score for major osteoporotic fracture ≥ 20, 25% of the women and 17% of the men received AODs. The strongest predictors for AODs were high age in women and use of glucocorticoids among men.
To examine the use of anti-osteoporotic drugs (AODs) and to identify predictors for prescriptions.
Data were obtained from the Nord-Trøndelag Health Study (HUNT3) performed in 2006–2008 and the Norwegian Prescription Database, including 15,075 women and 13,386 men aged 50–85 years. Bone mineral density (BMD) in the femoral neck was measured in a subgroup of 4538 women and 2322 men. High fracture risk was defined as a FRAX score for major osteoporotic fracture (MOF) ≥ 20%; in the subgroup with BMD, high risk was in addition defined as FRAXMOF ≥ 20% or T-score ≤ − 2.5. Hazard ratios (HRs) for predictors of incident use of AODs within 2 years after HUNT3 were estimated by Cox’ proportional hazards model.
Among individuals with FRAX MOF ≥ 20%, 25% of the women and 17% of the men were treated with AODs. Among those with FRAX MOF < 20%, 3% and 1% were treated, respectively. In the subgroup with BMD measurement, 24% of the women and 16% of the men at high risk of fractures were treated, compared to 3 and 1% in women and men not fulfilling the criteria. In women, high age was the strongest predictor for treatment (HR 3.84: 95% confidence interval 2.81–5.24), followed by use of glucocorticoids (GCs) (2.68:1.84–3.89). In men, predictors were use of GCs (5.28: 2.70–10.35) followed by multimorbidity (3.16:1.31–7.63). In the subgroup with BMD, T-score ≤ − 2.5 was the strongest predictor (women 3.98:2.67–5.89; men 13.31:6.17–28.74).
This study suggests an undertreatment of AODs in individuals at high risk of fracture.
KeywordsOsteoporosis Anti-osteoporotic drugs General population studies HUNT
The Nord-Trøndelag Health Study (The HUNT Study) is in collaboration between HUNT Research Centre (Faculty of Medicine, Norwegian University of Science and Technology NTNU), Nord-Trøndelag County Council, Central Norway Health Authority, and the Norwegian Institute of Public Health.
MH received a postdoctoral fellowship grant from the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).
Compliance with ethical standards
Conflicts of interests
BA has institutional research contracts with UCB and Novartis with funds paid to the institutions.
US has received research grants from or served as a Principal Investigator in studies conducted by Amgen, Eli Lilly, Novartis, Merck and Wyeth pharmaceuticals.
MH, SS, HM, AD, AJS, AL, ES and BS have no disclosures.
- 3.Cheng SY, Levy AR, Lefaivre KA, Guy P, Kuramoto L, Sobolev B (2011) Geographic trends in incidence of hip fractures: a comprehensive literature review. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 22:2575–2586CrossRefGoogle Scholar
- 4.Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C, on behalf of the IOFWGoE, Quality of L (2012) A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA 23:2239–2256Google Scholar
- 5.(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. AmJMed 94:646–650Google Scholar
- 6.(1994) Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 843:1–129Google Scholar
- 7.Crandall CJ, Newberry SJ, Diamant A, et al. (2012) Treatment to prevent fractures in men and women with low bone density or osteoporosis: update of a 2007 report. Rockville MDGoogle Scholar
- 11.Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, McCloskey EV, Jonsson B, Kanis JA (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRefPubMedPubMedCentralGoogle Scholar
- 12.(2005) Norwegian guidelines for prevention and treatment of osteoporosis and osteoporotic fracturesGoogle Scholar
- 16.Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV (2016) A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos 11:25CrossRefPubMedPubMedCentralGoogle Scholar
- 17.Papaioannou A, Morin S, Cheung AM, et al. (2010) 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: summary. CMAJ : Can Med Assoc J = J de l'Association medicale canadienne 182:1864–1873, 2010Google Scholar
- 18.Siris ES, Adler R, Bilezikian J, Bolognese M, Dawson-Hughes B, Favus MJ, Harris ST, Jan de Beur SM, Khosla S, Lane NE, Lindsay R, Nana AD, Orwoll ES, Saag K, Silverman S, Watts NB (2014) The clinical diagnosis of osteoporosis: a position statement from the National Bone Health Alliance Working Group. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 25:1439–1443CrossRefGoogle Scholar
- 19.Finnes TE, Syversen U, Bakke Å, Høiberg M, Eriksen EF (2015) National guidelines in endocrinology, osteoporosis. http://www.helsebiblioteket.no/retningslinjer/endokrinologi-veileder/osteoporose-og-paratyroidea/osteoporose
- 20.(2015) The Norwegian Society for rheumatology: osteoporosis: investigation, treatment and follow-up http://legeforeningen.no/PageFiles/229641/Osteoporose%20%202015.pdf
- 21.Wastesson JW, Ringback Weitoft G, Parker MG, Johnell K (2013) Educational level and use of osteoporosis drugs in elderly men and women: a Swedish nationwide register-based study. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 24:433–442CrossRefGoogle Scholar
- 22.Krokstad S, Langhammer A, Hveem K, Holmen T, Midthjell K, Stene T, Bratberg G, Heggland J, Holmen J (2012) Cohort profile: the HUNT study, Norway. Int J EpidemiolGoogle Scholar
- 23.Hoff M, Meyer HE, Skurtveit S, Langhammer A, Sogaard AJ, Syversen U, Dhainaut A, Skovlund E, Abrahamsen B, Schei B (2017) Validation of FRAX and the impact of self-reported falls among elderly in a general population: the HUNT study, Norway. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USAGoogle Scholar
- 24.The Norwegian Prescription Database. The Norwegian Institute of Public Health. http://www.norpd.no/
- 25.Furu K (2008) Establishment of the nationwide Norwegian Prescription Database (NorPD)—new opportunities for research in pharmacoepidemiology in Norway. Norsk Epidemiologi:129–136Google Scholar
- 26.(2012) WHO Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. Norway: OsloGoogle Scholar
- 27.(2004, revised 2014) Regulations concerning food supplement in Norway https://lovdata.no/dokument/SF/forskrift/2004-05-20-755Google Scholar
- 34.Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356:1809–1822CrossRefPubMedGoogle Scholar
- 37.Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mellström D, Oefjord ES, Marcinowska-Suchowierska E, Salmi J, Mulder H, Halse J, Sawicki AZ, Mitlak BH (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344:1434–1441CrossRefPubMedGoogle Scholar
- 39.Borgstrom F, Strom O, Coelho J, Johansson H, Oden A, McCloskey EV, Kanis JA (2010) The cost-effectiveness of risedronate in the UK for the management of osteoporosis using the FRAX. Osteoporos Int: J Established Result Cooperation Between Eur Found Osteoporos Natl Osteoporos Found USA 21:495–505CrossRefGoogle Scholar
- 45.Rossouw JE, Anderson GL, Prentice RL, LaCroix A, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288:321–333CrossRefPubMedGoogle Scholar